K
Katharina Fink
Researcher at Karolinska University Hospital
Publications - 46
Citations - 1531
Katharina Fink is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 13, co-authored 32 publications receiving 1081 citations. Previous affiliations of Katharina Fink include University of Gothenburg & Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna,Peter Alping,Joachim Burman,Katharina Fink,Anna Fogdell-Hahn,Martin Gunnarsson,Jan Hillert,Annette Langer-Gould,Jan Lycke,Petra Nilsson,Jonatan Salzer,Anders Svenningsson,Magnus Vrethem,Tomas Olsson,Fredrik Piehl,Fredrik Piehl,Thomas Frisell +16 more
TL;DR: Patients with MS are at a generally increased risk of infections, and this differs by treatment; among newer treatments, off-label use of rituximab was associated with the highest rate of serious infections.
Journal ArticleDOI
Rituximab in multiple sclerosis : a retrospective observational study on safety and efficacy
Jonatan Salzer,Rasmus Svenningsson,Peter Alping,Lenka Novakova,Anna Björck,Katharina Fink,Protik Islam-Jakobsson,Clas Malmeström,Markus Axelsson,Mattias Vågberg,Peter Sundström,Jan Lycke,Fredrik Piehl,Anders Svenningsson +13 more
TL;DR: This study provides Class IV evidence that for patients with MS, rituximab is safe and effective, and is similar to those reported in previous randomized controlled trials on B-cell depletion therapy in MS.
Journal ArticleDOI
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Peter Alping,Thomas Frisell,Lenka Novakova,Protik Islam-Jakobsson,Jonatan Salzer,Anna Björck,Markus Axelsson,Clas Malmeström,Katharina Fink,Jan Lycke,Anders Svenningsson,Anders Svenningsson,Fredrik Piehl +12 more
TL;DR: Many JC virus antibody‐positive relapsing–remitting multiple sclerosis patients who are stable on natalizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy.
Journal ArticleDOI
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Nikolai Madrid Scheller,Henrik Svanström,Björn Pasternak,Lisen Arnheim-Dahlström,Karin Sundström,Katharina Fink,Anders Hviid +6 more
TL;DR: In this study with nationwide coverage of 2 Scandinavian countries, qHPV vaccination was not associated with the development of multiple sclerosis or other demyelinating diseases, and findings do not support concerns about a causal relationship.
Journal ArticleDOI
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Nicky Dunn,Alexander Juto,Malin Ryner,Ali Manouchehrinia,Luca Piccoli,Katharina Fink,Fredrik Piehl,Anna Fogdell-Hahn +7 more
TL;DR: Rituximab treatment is associated with a high degree of ADAs, which correlates with efficacy of B-cell depletion; however, the clinical relevance ofADAs remains uncertain.